The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Prescription Drug Cost Sharing: Associations With Medication and Medical Utilization and Spending and Health
Open accessAbstract
CONTEXT: Prescription drugs are instrumental to managing and preventing chronic disease. Recent changes in US prescription drug cost sharing could affect access to them. OBJECTIVE: To synthesize published evidence on the associations among cost-sharing features of prescription drug benefits and use of prescription drugs, use of nonpharmaceutical services, and health outcomes. DATA SOURCES: We searched PubMed for studies published in English between 1985 and 2006. STUDY SELECTION AND DATA EXTRACTION: Among 923 articles found in the search, we identified 132 articles examining the associations between prescription drug plan cost-containment measures, including co-payments, tiering, or coinsurance (n = 65), pharmacy benefit caps or monthly prescription limits (n = 11), formulary restrictions (n = 41), and reference pricing (n = 16), and salient outcomes, including pharmacy utilization and spending, medical care utilization and spending, and health outcomes. RESULTS: Increased cost sharing is associated with lower rates of drug treatment, worse adherence among existing users, and more frequent discontinuation of therapy. For each 10% increase in cost sharing, prescription drug spending decreases by 2% to 6%, depending on class of drug and condition of the patient. The reduction in use associated with a benefit cap, which limits either the coverage amount or the number of covered prescriptions, is consistent with other cost-sharing features. For some chronic conditions, higher cost sharing is associated with increased use of medical services, at least for patients with congestive heart failure, lipid disorders, diabetes, and schizophrenia. While low-income groups may be more sensitive to increased cost sharing, there is little evidence to support this contention. CONCLUSIONS: Pharmacy benefit design represents an important public health tool for improving patient treatment and adherence. While increased cost sharing is highly correlated with reductions in pharmacy use, the long-term consequences of benefit changes on health are still uncertain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interventions to Enhance Patient Adherence to Medication Prescriptions: Scientific Review
McDonald, H. P., Garg, A. X., & Haynes, R. B. (2002) · JAMA · doi:10.1001/jama.288.22.2868 · Cited by 1,176
Adverse Events Associated With Prescription Drug Cost-Sharing Among Poor and Elderly Persons
Tamblyn, R. (2001) · JAMA · doi:10.1001/jama.285.4.421 · Cited by 873
Pharmacy Benefits and the Use of Drugs by the Chronically Ill
Goldman, D. P. (2004) · JAMA · doi:10.1001/jama.291.19.2344 · Cited by 530
Self-citationEffects of Medicaid Drug-Payment Limits on Admission to Hospitals and Nursing Homes
Soumerai, S. B., Ross-Degnan, D., Avorn, J., McLaughlin, T. J., & Choodnovskiy, I. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110103251505 · Cited by 505
Soumerai, S. B., McLaughlin, T. J., Ross-Degnan, D., Casteris, C. S., & Bollini, P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409083311006 · Cited by 480
Payment Restrictions for Prescription Drugs under Medicaid
Soumerai, S. B., Avorn, J., Ross-Degnan, D., & Gortmaker, S. (1987) · New England Journal of Medicine · doi:10.1056/nejm198708273170906 · Cited by 409
Unintended Consequences of Caps on Medicare Drug Benefits
Hsu, J., Price, M., Huang, J., Brand, R., Fung, V., Hui, R., Fireman, B., Newhouse, J. P., & Selby, J. V. (2006) · New England Journal of Medicine · doi:10.1056/nejmsa054436 · Cited by 371
The Effect of Incentive-Based Formularies on Prescription-Drug Utilization and Spending
Huskamp, H. A., Deverka, P. A., Epstein, A. M., Epstein, R. S., McGuigan, K. A., & Frank, R. G. (2003) · New England Journal of Medicine · doi:10.1056/nejmsa030954 · Cited by 334
Ellis, J. J., Erickson, S. R., Stevenson, J. G., Bernstein, S. J., Stiles, R. A., & Fendrick, A. M. (2004) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2004.30516.x · Cited by 323
The demand for prescription drugs as a function of cost-sharing
Leibowitz, A., Manning, W. G., & Newhouse, J. P. (1985) · Social Science & Medicine · doi:10.1016/0277-9536(85)90161-3 · Cited by 286
Employer Drug Benefit Plans and Spending on Prescription Drugs
Joyce, G. F. (2002) · JAMA · doi:10.1001/jama.288.14.1733 · Cited by 228
Self-citationAre The Benefits Of Newer Drugs Worth Their Cost? Evidence From The 1996 MEPS
Lichtenberg, F. R. (2001) · Health Affairs · doi:10.1377/hlthaff.20.5.241 · Cited by 214
Intensive Statin Therapy — A Sea Change in Cardiovascular Prevention
Topol, E. J. (2004) · New England Journal of Medicine · doi:10.1056/nejme048061 · Cited by 197
Harris, B. L., Stergachis, A., & Ried, L. D. (1990) · Medical Care · doi:10.1097/00005650-199010000-00005 · Cited by 188
Outcomes of Reference Pricing for Angiotensin-Converting–Enzyme Inhibitors
Schneeweiss, S., Walker, A. M., Glynn, R. J., Maclure, M., Dormuth, C., & Soumerai, S. B. (2002) · New England Journal of Medicine · doi:10.1056/nejmsa003087 · Cited by 178
Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy.
Goldman, D. P., Joyce, G., & Karaca‐Mandic, P. (2006) · PubMed · Cited by 173
Self-citationWho Bears The Burden Of Medicaid Drug Copayment Policies?
Stuart, B., & Zacker, C. (1999) · Health Affairs · doi:10.1377/hlthaff.18.2.201 · Cited by 167
Effect of a Three-Tier Prescription Copay on Pharmaceutical and Other Medical Utilization
Motheral, B., & Fairman, K. A. (2001) · Medical Care · doi:10.1097/00005650-200112000-00005 · Cited by 161
Tseng, C., Brook, R. H., Keeler, E., Steers, W. N., & Mangione, C. M. (2004) · JAMA · doi:10.1001/jama.292.8.952 · Cited by 150
Smalley, W. E., Griffin, M. R., Fought, R. L., Sullivan, L., & Ray, W. A. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506153322406 · Cited by 141
Financial Incentives And Drug Spending In Managed Care
Hillman, A. L., Pauly, M. V., Escarce, J. J., Ripley, K., Gaynor, M., Clouse, J., & Ross, R. (1999) · Health Affairs · doi:10.1377/hlthaff.18.2.189 · Cited by 137
Drug Copayment and Adherence in Chronic Heart Failure: Effect on Cost and Outcomes
Cole, J. A., Norman, H. S., Weatherby, L. B., & Walker, A. M. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.8.1157 · Cited by 130
Impact of statin copayments on adherence and medical care utilization and expenditures.
Gibson, T. B., Mark, T. L., Axelsen, K. J., Baser, O., Rublee, D. A., & McGuigan, K. A. (2006) · PubMed · Cited by 125
Winkelmann, R. (2004) · Health Economics · doi:10.1002/hec.868 · Cited by 118
Johnson, R. E., Goodman, M. J., Hornbrook, M. C., & Eldredge, M. B. (1997) · Medical Care · doi:10.1097/00005650-199711000-00004 · Cited by 112
The differential impact of copayment on drug use in a Medicaid population.
Reeder, C. E., & Nelson, A. A. (1985) · PubMed · Cited by 111
Medicaid Prior-Authorization Programs and the Use of Cyclooxygenase-2 Inhibitors
Fischer, M. A., Schneeweiß, S., Avorn, J., & Solomon, D. H. (2004) · New England Journal of Medicine · doi:10.1056/nejmsa042770 · Cited by 111
Ability to Pay and the Decision to Medicate
Stuart, B., & Grana, J. R. (1998) · Medical Care · doi:10.1097/00005650-199802000-00009 · Cited by 110
Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.
Schneeweiß, S., Soumerai, S. B., Glynn, R. J., Maclure, M., Dormuth, C. R., & Walker, A. M. (2002) · PubMed Central · Cited by 102
The effects of prescription drug copayments on statin adherence.
Gibson, T. B., Mark, T. L., McGuigan, K. A., Axelsen, K. J., & Wang, S. S. (2006) · PubMed · Cited by 101
Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization.
Landsman, P. B., Yu, W., Liu, X., Teutsch, S. M., & Berger, M. L. (2005) · PubMed · Cited by 99
Johnson, R. E., Goodman, M. J., Hornbrook, M. C., & Eldredge, M. B. (1997) · Europe PMC (PubMed Central) · Cited by 99
Roblin, D. W., Platt, R. G., Goodman, M. J., Hsu, J., Nelson, W. W., Smith, D. H., Andrade, S. E., & Soumerai, S. B. (2005) · Medical Care · doi:10.1097/01.mlr.0000178216.23514.b7 · Cited by 98
The effect of patient charges on the utilisation of prescription medicines
OʼBrien, B. J. (1989) · Journal of Health Economics · doi:10.1016/0167-6296(89)90011-8 · Cited by 98
Taira, D. A., Wong, K. S., Frech‐Tamas, F., & Chung, R. S. (2006) · PubMed · Cited by 94
Foxman, B., Valdez, R. B., Lohr, K. N., Goldberg, G. A., Newhouse, J. P., & Brook, R. H. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90176-7 · Cited by 92
Reducing patient drug acquisition costs can lower diabetes health claims.
Mahoney, J. J. (2005) · PubMed · Cited by 88
Job-Based Health Benefits In 2002: Some Important Trends
Gabel, J. R., Levitt, L., Holve, E., Pickreign, J. D., Whitmore, H., Dhont, K., Hawkins, S., & Rowland, D. (2002) · Health Affairs · doi:10.1377/hlthaff.21.5.143 · Cited by 86
Effect of Tiered Prescription Copayments on the Use of Preferred Brand Medications
Rector, T. S., Finch, M. D., Danzon, P. M., et al. (2003) · Medical Care · doi:10.1097/01.mlr.0000053022.47132.82 · Cited by 85
Martin, B. C., & McMillan, J. A. (1996) · Medical Care · doi:10.1097/00005650-199607000-00003 · Cited by 81
Delate, T., MAGER, D. E., Sheth, J., & Motheral, B. R. (2005) · PubMed · Cited by 79
Medicare Beneficiaries??? Management of Capped Prescription Benefits
Cox, E. R., Jernigan, C., Coons, S. J., et al. (2001) · Medical Care · doi:10.1097/00005650-200103000-00009 · Cited by 75
Fairman, K. A., Motheral, B. R., & Henderson, R. R. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)90099-3 · Cited by 75
The effects of copayments and generic substitution on the use and costs of prescription drugs.
Smith, D. G. (1993) · PubMed · Cited by 73
Dormuth, C. R., Glynn, R. J., Neumann, P. J., Maclure, M., Brookhart, A. M., & Schneeweiß, S. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.06.007 · Cited by 73
Huskamp, H. A., Deverka, P. A., Epstein, A. M., Epstein, R. S., McGuigan, K. A., Muriel, A. C., & Frank, R. G. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.4.435 · Cited by 72
Pilote, L., Beck, C. A., Richard, H., & Eisenberg, M. J. (2002) · Europe PMC (PubMed Central) · Cited by 70
Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers
Schneeweiß, S., Soumerai, S. B., Maclure, M., Dormuth, C., Walker, A. M., & Glynn, R. J. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00227-3 · Cited by 68
Schneeweiß, S., Maclure, M., Carleton, B., Glynn, R. J., & Avorn, J. (2004) · BMJ · doi:10.1136/bmj.38020.698194.f6 · Cited by 68
Motheral, B., & Henderson, R. (1999) · PubMed · Cited by 67
Huskamp, H. A., Epstein, A. M., & Blumenthal, D. (2003) · Health Affairs · doi:10.1377/hlthaff.22.3.149 · Cited by 66
Charging for health care: Evidence on the utilisation of NHS prescribed drugs
Ryan, M., & Birch, S. (1991) · Social Science & Medicine · doi:10.1016/0277-9536(91)90022-5 · Cited by 64
Insurance Choice and the Demand for Prescription Drugs
Coulson, N. E., & Stuart, B. (1995) · Southern Economic Journal · doi:10.2307/1060746 · Cited by 62
Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures?
Andersson, K., Petzold, M. G., Sonesson, C., Lönnroth, K., & Carlsten, A. (2006) · Health Policy · doi:10.1016/j.healthpol.2006.01.007 · Cited by 60
Anis, A. H. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.045146 · Cited by 60
Medicaid Cost Containment And Access To Prescription Drugs
Cunningham, P. J. (2005) · Health Affairs · doi:10.1377/hlthaff.24.3.780 · Cited by 57
Prescription Drug Utilization Following Patient Co-Payment Changes in Australia
McManus, P. R., DONNELLY, N., HENRY, D., Hall, W., Primrose, J. G., & Lindner, J. (1996) · Pharmacoepidemiology and Drug Safety · doi:10.1002/(sici)1099-1557(199611)5:6<385::aid-pds246>3.0.co;2-8 · Cited by 56
Blais, L., Couture, J., Rahme, E., & LeLorier, J. (2003) · Health Policy · doi:10.1016/s0168-8510(02)00158-6 · Cited by 55
A therapeutic substitution policy for proton pump inhibitors: Clinical and economic consequences
Schneeweiß, S., Maclure, M., Dormuth, C. R., Glynn, R. J., Canning, C. F., & Avorn, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.12.304 · Cited by 52
Wilson, J., Axelsen, K. J., & Tang, S. S. K. (2005) · PubMed · Cited by 51
Impact of an Annual Dollar Limit or "Cap" on Prescription Drug Benefits for Medicare Patients
Tseng, C. (2003) · JAMA · doi:10.1001/jama.290.2.222 · Cited by 49
Expanding Medicaid Drug Formulary Coverage
Kozmo, C. M., Reeder, C. E., & Lingle, E. W. (1990) · Medical Care · doi:10.1097/00005650-199010000-00010 · Cited by 49
Kozyrskyj, A. L., Mustard, C., Cheang, M., & Simons, F. E. R. (2001) · Europe PMC (PubMed Central) · Cited by 49
Hughes, D. J., & McGuire, A. (1995) · Health Economics · doi:10.1002/hec.4730040306 · Cited by 48
Artz, M. B., Hadsall, R. S., & Schondelmeyer, S. W. (2002) · American Journal of Public Health · doi:10.2105/ajph.92.8.1257 · Cited by 48
Kozyrskyj, A. L., Mustard, C., & Simons, F. E. R. (2001) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.155.11.1219 · Cited by 46
Methodological biases in estimating the burden of out-of-pocket expenses.
Goldman, D. P., & Smith, J. P. (2001) · PubMed · Cited by 45
Self-citationWang, J., Noel, J. M., Zuckerman, I. H., Miller, N. A., Shaya, F. T., & Mullins, C. D. (2006) · Medical Care Research and Review · doi:10.1177/1077558706293638 · Cited by 45
Nair, K. V., Wolfe, P., Valuck, R. J., et al. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.5.575 · Cited by 42
Pricing and Reimbursement of Pharmaceuticals in Sweden
Jönsson, B. (1994) · PharmacoEconomics · doi:10.2165/00019053-199400061-00013 · Cited by 39
HARTUNG, D., Touchette, D. R., Ketchum, K. L., Haxby, D. G., & GOLDBERG, B. (2004) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.09.013 · Cited by 39
Christian-Herman, J. L., Emons, M. F., & George, D. (2004) · Health Affairs · doi:10.1377/hlthaff.w4.455 · Cited by 38
Impact of Consumer Fees on Drug Utilisation
Smith, D. G., & Kirking, D. M. (1992) · PharmacoEconomics · doi:10.2165/00019053-199202040-00008 · Cited by 36
Effect of prescription benefit changes on medical care utilization in a Medicare HMO population.
Balkrishnan, R., Byerly, W. G., Camacho, F., Shrestha, A., & Anderson, R. T. (2001) · PubMed · Cited by 36
Gibson, T. B., McLaughlin, C. G., & Smith, D. G. (2005) · INQUIRY The Journal of Health Care Organization Provision and Financing · doi:10.5034/inquiryjrnl_42.3.293 · Cited by 35
Assessing the Effect of Taiwan???s Outpatient Prescription Drug Copayment Policy in the Elderly
Liu, S.-Z., & Romeis, J. C. (2003) · Medical Care · doi:10.1097/01.mlr.0000100579.91550.c4 · Cited by 34
Liu, S.-Z., & Romeis, J. C. (2004) · Health Policy · doi:10.1016/j.healthpol.2003.12.013 · Cited by 33
Ong, M., Catalano, R. A., & Hartig, T. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80082-6 · Cited by 33
Alternative insurance arrangements and the treatment of depression: what are the facts?
Berndt, E. R., Frank, R. G., & McGuire, T. G. (1997) · PubMed · Cited by 33
Lurk, J. T., DeJong, D. J., Woods, T. M., Knell, M. E., & Carroll, C. A. (2004) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/61.3.267 · Cited by 32
Evaluating reference-based pricing: initial findings and prospects.
Narine, L., Senathirajah, M., & Smith, T. (1999) · Europe PMC (PubMed Central) · Cited by 32
Roughead, E. E., Zhang, F., Ross‐Degnan, D., & Soumerai, S. B. (2006) · Medical Care · doi:10.1097/01.mlr.0000204056.31664.36 · Cited by 31
Plan-sponsor savings and member experience with point-of-service prescription step therapy.
Motheral, B. R., Henderson, R. R., & Cox, E. R. (2004) · PubMed · Cited by 30
Frontiers in Health Policy Research, Volume 7
Crown, W. H., Berndt, E. R., Baser, O., et al. (n.d.) · RePEc: Research Papers in Economics · Cited by 30
The effect of a closed formulary on prescription drug use and costs.
Motheral, B., & Henderson, R. R. (2000) · PubMed · Cited by 29
Impact of Medicaid Preferred Drug Lists on Therapeutic Adherence
Ridley, D. B., & Axelsen, K. J. (2006) · PharmacoEconomics · doi:10.2165/00019053-200624003-00006 · Cited by 29
Dunn, J. D., Cannon, E., Mitchell, M. P., & Curtiss, F. R. (2006) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2006.12.4.294 · Cited by 29
Three-Tiered–Copayment Drug Coverage and Use of Nonsteroidal Anti-inflammatory Drugs
Briesacher, B. A., Kamal‐Bahl, S. J., Hochberg, M. C., Orwig, D., & Kahler, K. H. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.15.1679 · Cited by 29
Nair, K. V., Wolfe, P., Valuck, R. J., et al. (2003) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2003.9.2.123 · Cited by 28
Cost Savings Using a Stepped-Care Prescribing Protocol for Nonsteroidal Anti-inflammatory Drugs
Jones, D. L. (1996) · JAMA · doi:10.1001/jama.1996.03530360036035 · Cited by 27
Murawski, M. M., & Abdelgawad, T. (2005) · PubMed · Cited by 26
McCombs, J. S., Shi, L., Stimmel, G. L., & Croghan, T. W. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)80090-x · Cited by 25
Impact of a Cost‐Sharing Drug Insurance Plan on Drug Utilization Among Older People
Blais, L., Boucher, J., Couture, J., Rahme, E., & LeLorier, J. (2001) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2001.49084.x · Cited by 25
Gleason, P. P., Williams, C. E., Hrdy, S., Hartwig, S. C., & Lassen, D. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.2005.25.7.924 · Cited by 23
Streja, D. A., Hui, R. L., Streja, E., & McCombs, J. S. (1999) · PubMed · Cited by 23
West, D. S., Johnson, J. T., & Hong, S. H. (2006) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2006.12.1.25 · Cited by 22
The impact of outpatient drug benefits on the use and costs of health care services for the elderly.
Ew, L., Kw, K., & Wr, K. (1987) · PubMed · Cited by 19
Cromwell, D. M., Bass, E. B., Steinberg, E. P., et al. (1999) · PubMed · Cited by 18
The effect of access restrictions on the vintage of drugs used by Medicaid enrollees.
Lichtenberg, F. R. (2005) · PubMed · Cited by 18
An update on Americans' access to prescription drugs.
Reed, M. C. (2005) · PubMed · Cited by 18
Cited by
Zafar, S. Y., Peppercorn, J. M., Schrag, D., Taylor, D. H., Goetzinger, A. M., Zhong, X., & Abernethy, A. P. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0279 · Cited by 1,130
Full Coverage for Preventive Medications after Myocardial Infarction
Choudhry, N. K., Avorn, J., Glynn, R. J., Antman, E. M., Schneeweiss, S., Toscano, M., Reisman, L., Fernandes, J., Spettell, C., Lee, J. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmsa1107913 · Cited by 736
Gellad, W. F., Grenard, J. L., & Marcum, Z. A. (2011) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2011.02.004 · Cited by 692
Grenard, J. L., Munjas, B. A., Adams, J. L., Suttorp, M., Maglione, M., McGlynn, E. A., & Gellad, W. F. (2011) · Journal of General Internal Medicine · doi:10.1007/s11606-011-1704-y · Cited by 635
The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform
Kesselheim, A. S., Avorn, J., & Sarpatwari, A. (2016) · JAMA · doi:10.1001/jama.2016.11237 · Cited by 592
Metadata
- Authors
- Goldman, D. P., Joyce, G. F., & Zheng, Y.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2007-07-04
- Volume
- 298
- Issue
- 1
- Pages
- 61
- ISSN
- 0098-7484
- OpenAlex
- W1984959392
- Cited by
- 874
- References
- 100
- FWCI
- 126.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.